Genprex GNPX 深 沪
已收盘 08-01 16:00:00 美东时间
0.231
0.000
0.00%
华盛通- 最 高0.2359
- 今 开0.2333
- 成交量 117.82万股
- 最 低 0.22
- 昨 收 0.231
- 总市值 773.08万
- 52周最高 3.97
- 市盈率 静 --
- 换手率 3.52%
- 52周最低 0.2023
- 委 比 -5.26%
- 总股本 3346.68万
- 历史最高 778.00
- 量 比 1.30
- 振 幅 6.88%
- 历史最低 0.2023
- 每 手 1
- 风险率 3.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pluri (NASDAQ:PLUR) shares moved upwards by 24.0% to $5.99 during Tues...
07-02 05:05
Genprex Announces That Its Research Collaborators Presented Positive Preclinical Data And Research From Studies Of Gpx-002 At The 2025 American Diabetes Association 85th Scientific Session In Chicago
Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery SystemGenprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing
06-23 21:04
Genprex Enters $12.5M Stock Purchase Agreement
Genprex ( ($GNPX) ) has issued an update. On June 11, 2025, Genprex entered int...
06-12 05:51
Genprex to Participate at BIO 2025 International Convention
AUSTIN, Texas, June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
06-03 19:00
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
<p>Gain Therapeutics, Inc. announced an oral presentation at the GBA1 Meeting 2025 in Montreal, Canada, set for June 5-7. The presentation, scheduled for June 5 at 11:20 p.m. EST, will be delivered by Jonas Hannestad, M.D., Ph.D., the Company's Chief Medical Officer. Gain is focused on developing next-generation allosteric therapies, with its lead candidate, GT-02287, currently in a Phase 1b trial for Parkinson’s disease, and showing potential fo...
05-29 12:45
Genprex Q1 EPS $(0.26) Beats $(0.41) Estimate
Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.41) by 36.59 percent. This is a 92.95 percent increase over losses of $(3.69) per share from the same
05-13 05:35
Genprex Enters Sponsored Research Agreement With The University Of Pittsburgh To Study Diabetes Gene Therapy In Type 1 And Type 2 Diabetes
Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education
05-07 19:07
Genprex enters patent license agreement with NYU Langone Health
Genprex (NASDAQ:GNPX) said it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa Gene Therapy. The firm added that the therapy is under inv...
04-28 19:43
